Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Study uses simulation model to assess cost-effective eye screenings for Americans with diabetes

Study uses simulation model to assess cost-effective eye screenings for Americans with diabetes

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech's Lucentis Phase III trials in DME meets primary endpoints

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Statin drug may help prevent blindness in diabetics

Statin drug may help prevent blindness in diabetics

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Phase III RISE study of Lucentis for DME meets primary endpoint

Phase III RISE study of Lucentis for DME meets primary endpoint

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

CVVS scientist receives top UK award for ground-breaking research on vascular stem cells, eye disease

CVVS scientist receives top UK award for ground-breaking research on vascular stem cells, eye disease

Queen’s scientist awarded Royal Society Wolfson Research Merit Award

Queen’s scientist awarded Royal Society Wolfson Research Merit Award

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

DMP1 protein prevents endothelial cells to respond to VEGF

DMP1 protein prevents endothelial cells to respond to VEGF

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.